Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report issued on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on RVNC. Barclays reiterated an “equal weight” rating and issued a $7.00 price objective (down previously from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Guggenheim reiterated a “neutral” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. HC Wainwright restated a “neutral” rating and set a $6.60 target price on shares of Revance Therapeutics in a research note on Friday, November 8th. Finally, William Blair restated a “market perform” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Nine research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $9.66.

Revance Therapeutics Trading Up 1.1 %

Shares of NASDAQ:RVNC opened at $3.80 on Monday. The business has a 50-day moving average price of $5.30 and a 200 day moving average price of $4.45. The company has a market capitalization of $398.62 million, a price-to-earnings ratio of -1.97 and a beta of 0.95. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. As a group, equities research analysts predict that Revance Therapeutics will post -1.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Revance Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. LMR Partners LLP purchased a new stake in Revance Therapeutics in the third quarter valued at approximately $11,648,000. Capital World Investors increased its holdings in shares of Revance Therapeutics by 16.8% in the first quarter. Capital World Investors now owns 13,945,535 shares of the biopharmaceutical company’s stock valued at $68,612,000 after purchasing an additional 2,006,459 shares during the period. Integral Health Asset Management LLC acquired a new position in shares of Revance Therapeutics in the second quarter valued at approximately $1,285,000. Vanguard Group Inc. increased its holdings in shares of Revance Therapeutics by 6.5% in the first quarter. Vanguard Group Inc. now owns 5,398,406 shares of the biopharmaceutical company’s stock valued at $26,560,000 after purchasing an additional 328,781 shares during the period. Finally, Blair William & Co. IL increased its holdings in shares of Revance Therapeutics by 3.6% in the first quarter. Blair William & Co. IL now owns 329,267 shares of the biopharmaceutical company’s stock valued at $1,620,000 after purchasing an additional 11,318 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.